DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 165 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 1.08 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $3,596,000 | -71.2% | 368,042 | 0.0% | 0.00% | -66.7% |
| Q3 2021 | $12,506,000 | -9.6% | 368,042 | -2.6% | 0.00% | 0.0% |
| Q2 2021 | $13,834,000 | -5.0% | 377,879 | +16.3% | 0.00% | 0.0% |
| Q1 2021 | $14,567,000 | -41.2% | 324,868 | -25.1% | 0.00% | -50.0% |
| Q4 2020 | $24,762,000 | +8.5% | 433,882 | -2.5% | 0.01% | 0.0% |
| Q3 2020 | $22,821,000 | -1.5% | 444,860 | +14.6% | 0.01% | -14.3% |
| Q2 2020 | $23,176,000 | +213.9% | 388,079 | +116.4% | 0.01% | +133.3% |
| Q1 2020 | $7,384,000 | +5.9% | 179,355 | -46.0% | 0.00% | 0.0% |
| Q4 2018 | $6,974,000 | -64.0% | 332,261 | -33.5% | 0.00% | -50.0% |
| Q3 2018 | $19,360,000 | -1.6% | 500,000 | 0.0% | 0.01% | -14.3% |
| Q2 2018 | $19,675,000 | +1209.0% | 500,000 | +566.7% | 0.01% | +600.0% |
| Q1 2018 | $1,503,000 | -11.6% | 75,000 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $1,700,000 | +19.4% | 75,000 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $1,424,000 | – | 75,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 2,086,723 | $85,910,000 | 25.70% |
| SV Health Investors, LLC | 449,951 | $18,525,000 | 15.54% |
| Redmile Group, LLC | 5,116,263 | $210,637,000 | 5.90% |
| Eversept Partners, LP | 414,081 | $17,047,715 | 4.24% |
| Sunesis Advisors, LLC | 96,299 | $3,965,000 | 3.99% |
| Avoro Capital Advisors LLC | 2,000,000 | $82,340,000 | 2.78% |
| Opaleye Management Inc. | 222,000 | $9,140,000 | 2.42% |
| SECTORAL ASSET MANAGEMENT INC | 204,059 | $8,401,000 | 1.61% |
| Artal Group S.A. | 800,000 | $32,936,000 | 1.39% |
| Atika Capital Management LLC | 141,000 | $5,805,000 | 1.11% |